The present invention relates to the use of a novel anoctamin 1 (ANO1) inhibitory compound for preventing and treating brain tumors, and is completed by confirming that the compound can inhibit brain tumors by inhibiting the expression or activity of ANO1, which is a
calcium-dependent
chloride channel. The growth, migration, and proliferation of
brain tumor cells treated with the compound were significantly inhibited, and such inhibitory effects were shown to be superior to conventional ANO1 inhibitors. In particular, the compound of the present invention can simultaneously inhibit ANO1 and EGFR in
brain tumor cells, thereby exhibiting a strong anticancer effect through
dual inhibition of the two proteins, further enhancing the
efficacy of an anticancer agent when used in combination with an EGFR targeted anticancer agent, and inhibiting
cancer resistance. Therefore, the compound itself can be used as a
dual target anticancer agent of ANO1 and EGFR, and can also be used as a combination agent of EGFR
targeted therapy, and thus is expected to be variously utilized in the field of prevention and treatment of brain tumors.